Mirjam J. Knol

Mirjam J. Knol publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Mirjam J. Knol sits on this spectrum.

Mirjam J. Knol D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Mirjam J. Knol sits on this spectrum.

Best Publications

• Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial.

  Inge M. Haeck;Mirjam J. Knol;Onno ten Berge;Sara G.A. van Velsen

  221
  Citations

• Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections

  Unknown

  217
  Citations

• Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe

  Unknown

  203
  Citations

• Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination

  Germaine Hanquet;Pavla Krizova;Palle Valentiner-Branth;Shamez N. Ladhani

  172
  Citations

• The diagnostic value of specific IgE to Ara h 2 to predict peanut allergy in children is comparable to a validated and updated diagnostic prediction model

  Rob J.B. Klemans;Dianne Otte;Mirjam Knol;Edward F. Knol

  167
  Citations

• Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.

  Unknown

  129
  Citations

• Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community

  Bernhard Ultsch;Oliver Damm;Phillippe Beutels;Joke Bilcke

  128
  Citations

• Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study

  Mirjam J Knol;Susan J M Hahné;Jay Lucidarme;Helen Campbell

  103
  Citations

• Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands.

  Mirjam J Knol;Gertjan H J Wagenvoort;Elisabeth A M Sanders;Karin Elberse

  101
  Citations

• Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women

  Cees van Nieuwkoop;Willize E. van der Starre;Janneke E. Stalenhoef;Anna M. van Aartrijk

  101
  Citations

• E‐health in caring for patients with atopic dermatitis: a randomized controlled cost‐effectiveness study of internet‐guided monitoring and online self‐management training

  Unknown

  97
  Citations

• Large ongoing measles outbreak in a religious community in the Netherlands since May 2013.

  Unknown

  93
  Citations

• Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial.

  Judith Spijkerman;Reinier H. Veenhoven;Alienke J. Wijmenga-Monsuur;Karin E. M. Elberse

  92
  Citations

• Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group.

  M. de Graaf;M.F. Raphael;C.C. Breugem;M.J. Knol

  89
  Citations

• Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021.

  Brechje de Gier;Stijn Andeweg;Rosa Joosten;Ronald Ter Schegget

  86
  Citations

• Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial.

  Daan Barug;Inge Pronk;Marlies A. van Houten;Florens G. A. Versteegh

  85
  Citations

• Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024

  Unknown

  75
  Citations

• Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with serology

  Unknown

  73
  Citations

• Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018.

  Mirjam J. Knol;Wilhelmina L. M. Ruijs;Laura Antonise-Kamp;Hester E. de Melker

  69
  Citations

• Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021.

  Brechje de Gier;Stijn Andeweg;Jantien A Backer;Rivm Covid surveillance

  67
  Citations